Cargando…

Toward lentiviral vectors for antiangiogenic ocular gene therapy

Detalles Bibliográficos
Autores principales:	Askou, Anne Louise, Jakobsen, Thomas Stax, Corydon, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474565/ https://www.ncbi.nlm.nih.gov/pubmed/37663649 http://dx.doi.org/10.1016/j.omtm.2023.08.007

Ejemplares similares

Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors
por: Askou, Anne Louise, et al.
Publicado: (2015)

Associations between the Complement System and Choroidal Neovascularization in Wet Age-Related Macular Degeneration
por: Jensen, Emilie Grarup, et al.
Publicado: (2020)

Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy
por: Askou, Anne Louise, et al.
Publicado: (2019)

Improved Lentiviral Gene Delivery to Mouse Liver by Hydrodynamic Vector Injection through Tail Vein
por: Dalsgaard, Trine, et al.
Publicado: (2018)

Lentiviral Vectors for Ocular Gene Therapy
por: Arsenijevic, Yvan, et al.
Publicado: (2022)

25 years of maturation: A systematic review of RNAi in the clinic
por: Corydon, Ida Juhl, et al.
Publicado: (2023)

Sortilin Inhibition Protects Neurons From Degeneration in the Diabetic Retina
por: Jakobsen, Thomas Stax, et al.
Publicado: (2023)

In Vivo Knockout of the Vegfa Gene by Lentiviral Delivery of CRISPR/Cas9 in Mouse Retinal Pigment Epithelium Cells
por: Holmgaard, Andreas, et al.
Publicado: (2017)

Animal Models of Choroidal Neovascularization: A Systematic Review
por: Fabian-Jessing, Bjørn K., et al.
Publicado: (2022)

Non-Primate Lentiviral Vectors and Their Applications in Gene Therapy for Ocular Disorders
por: Cavalieri, Vincenzo, et al.
Publicado: (2018)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification
por: Haldrup, Jakob, et al.
Publicado: (2023)

Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I
por: Ou, Li, et al.
Publicado: (2016)

Lentiviral Vectors and Cystic Fibrosis Gene Therapy
por: Castellani, Stefano, et al.
Publicado: (2010)

Development of lentiviral vectors for gene therapy of arthritis
por: Militello, M, et al.
Publicado: (2001)

Local Adenoviral Delivery of Vascular Endothelial Growth Factor C Induces Lymphangiogenesis in the Conjunctiva in Rabbits
por: Rasic, Dusan, et al.
Publicado: (2023)

Subretinal Saline Protects the Neuroretina From Thermic Damage During Laser Induction of Experimental Choroidal Neovascularization in Pigs
por: Hansen, Silja, et al.
Publicado: (2021)

Brain-targeted ex vivo lentiviral gene therapy: Implications for MPS and beyond
por: Bradbury, Allison M.
Publicado: (2023)

The feasibility of incorporating Vpx into lentiviral gene therapy vectors
por: McAllery, Samantha A, et al.
Publicado: (2016)

Gene Therapy Applications of Non-Human Lentiviral Vectors
por: Munis, Altar M.
Publicado: (2020)

Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases
por: Poletti, Valentina, et al.
Publicado: (2021)

VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy
por: Alsing, Sidsel, et al.
Publicado: (2022)

Slow and steady wins the race: Optimizing lentiviral vector production for efficient clinical-scale manufacturing
por: McCarron, Alexandra
Publicado: (2023)

Toward Tightly Tuned Gene Expression Following Lentiviral Vector Transduction
por: Page, Audrey, et al.
Publicado: (2020)

Toward Personalized Gene Therapy: Characterizing the Host Genetic Control of Lentiviral-Vector-Mediated Hepatic Gene Delivery
por: Suwanmanee, Thipparat, et al.
Publicado: (2017)

Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

Production of lentiviral vectors
por: Merten, Otto-Wilhelm, et al.
Publicado: (2016)

Lentiviral Vector Bioprocessing
por: Perry, Christopher, et al.
Publicado: (2021)

More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation
por: Toon, Kamilla, et al.
Publicado: (2021)

Lentiviral Vector Gene Transfer to Porcine Airways
por: Sinn, Patrick L, et al.
Publicado: (2012)

Targeted Knockout of the Vegfa Gene in the Retina by Subretinal Injection of RNP Complexes Containing Cas9 Protein and Modified sgRNAs
por: Holmgaard, Andreas Braae, et al.
Publicado: (2021)

Recent translational research: antiangiogenic therapy for breast cancer – where do we stand?
por: Miller, Kathy D
Publicado: (2004)

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019)

Safe and efficient lentiviral vector integration with HSC-targeted gene therapy
por: Radtke, Stefan, et al.
Publicado: (2023)

Cell and Tissue Gene Targeting with Lentiviral Vectors
por: Escors, David, et al.
Publicado: (2012)

Maximizing lentiviral vector gene transfer in the CNS
por: Humbel, Morgane, et al.
Publicado: (2020)

Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?
por: Deng, Longfei, et al.
Publicado: (2022)

Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID
por: Charrier, Sabine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7r1mvkgqfau3tr23l5h4t4vnul